Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study.

ABSTRACT: Relapsed or refractory high-risk neuroblastoma (R/R HR-NB) is associated with a poor prognosis. Although 5 cycles of anti-GD2 immunotherapy with dinutuximab beta show efficacy, the regimen needs optimization. The present study evaluated the use of extended dinutuximab beta immunotherapy combined with chemotherapy in pediatric patients with R/R NB. In this single-center retrospective study, children with a median age 5.1 years (range, 2.0-11.1 years) with R/R HR-NB who were treated with >5 cycles of dinutuximab beta (10 mg/m²/day for 10-days per 35-day cycle), granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin, plus chemotherapy, were included. The primary outcome of the study was objective response rate (ORR). Secondary outcomes included disease control r

SUBMITTER: Gong Z 

PROVIDER: S-EPMC12754637 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature